3',5'-cyclic adenosine monophosphate phosphodiesterase (cAMP-PDE)

3',5'-cyclic adenosine monophosphate phosphodiesterase (cAMP-PDE) is a family of enzymes that catalyze the hydrolysis of the second messenger cyclic adenosine monophosphate (cAMP) into 5'-adenosine monophosphate (5'-AMP) (UniProt, 2024). By regulating the intracellular concentration of cAMP, these enzymes play a pivotal role in modulating signal transduction pathways that control immune cell activation, cardiac contractility, and smooth muscle relaxation (StatPearls, 2023). The cAMP-PDE family includes several isoforms, with PDE4, PDE7, and PDE8 being highly selective for cAMP, while others like PDE1, PDE2, and PDE3 exhibit dual specificity for both cAMP and cGMP (NIH, 2020). Dysregulation of these enzymes is associated with various inflammatory and respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), where increased PDE activity leads to reduced cAMP levels and enhanced pro-inflammatory signaling (PubMed, 2021). Pharmacological inhibition of cAMP-PDEs, particularly the PDE4 isoform, is a validated therapeutic approach used to treat conditions like psoriasis, psoriatic arthritis, and atopic dermatitis by increasing intracellular cAMP and suppressing cytokine production (PubChem, 2024). Despite their therapeutic potential, the clinical use of cAMP-PDE inhibitors is often hampered by side effects such as nausea, emesis, and headache, which are primarily attributed to the inhibition of PDE4 in the central nervous system and gastrointestinal tract (Wikipedia, 2024). Consequently, current drug development efforts are focused on identifying isoform-specific or tissue-targeted inhibitors to improve the safety profile and therapeutic index of these agents (Journal of Medicinal Chemistry, 2022).

Other names

cAMP phosphodiesteraseCyclic AMP phosphodiesterasePDEcAMP-specific phosphodiesterase3',5'-cyclic-AMP phosphodiesterase

Competitive inhibition of the catalytic site of the phosphodiesterase enzyme, preventing the hydrolysis of 3',5'-cyclic adenosine monophosphate (cAMP) to 5'-adenosine monophosphate (5'-AMP), thereby increasing intracellular cAMP levels and activating protein kinase A (PKA) pathways.